12 results about "LACTOSE MONOHYDRATE" patented technology

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a pharmaceutical composition containing briracetam and a preparation method of the pharmaceutical composition. A pharmaceutical composition of the present application comprises a particle having an intra-particle phase and an extra-particle phase, the particle comprising, based on the total weight of the particle: Briracetam present in the intra-particle phase; the diluent in the particle inner phase is lactose monohydrate and lactose anhydrous in a weight ratio of 1: (0.5-2); a disintegrant present in the particulate inner phase and the particulate outer phase; and a lubricant present in the particulate outer phase. By controlling the weight ratio of the diluent types, the defect of easy sticking is improved under the condition that an adhesive beta-cyclodextrin is not added, and it is guaranteed that intermediate particles are tableted smoothly and are convenient to form; besides, by controlling the particle size of the active components and the dosage of the external phase disintegrating agent in the particles, the prepared briracetam preparation has the dissolution rate and bioequivalence equivalent to those of the original tablet, and the stability is superior to that of the original tablet.

The present disclosure provides oral dosage forms comprising about 8.75% w / w deuruxolitinib phosphate, about 50% to about 60% w / w microcrystalline cellulose, about 25% to about 35% w / w lactose monohydrate, about 3% to about 6% w / w polyvinylpyrrolidone, about 2% to about 4% w / w hydroxypropyl cellulose, about 0.25% to about 0.75% w / w colloidal silicon dioxide, and about 0.25% to about 0.75% w / w magnesium stearate.

The application relates to a celecoxib capsule composition and belongs to the technical field of pharmaceutical preparations. The celecoxib capsule composition is prepared from the following components in percentage by weight: celecoxib 74.1%, lactose monohydrate 16.4%-17.4%, arginine 1.0%-2.0%, sodium dodecyl sulfate 3.0%, povidone (K30) 2.5%, cross-linked sodium carboxymethyl cellulose 1.0%, and magnesium stearate 1.0%. The problem that the dissolution curve of the celecoxib capsule is significantly slowed down during storage is solved by adding appropriate arginine in the prescription.

A novel compound complex that has no side effects on a liver and is used to alleviate the toxicity of an acetaminophen (APAP) drug to the liver. The composition of the compound consists of (a) acetaminophen in a pharmaceutically effective amount and (b) a commonly-used safe and pharmaceutically acceptable excipient that can be combined with one or more of two drugs to reduce the toxicity of a drug metabolized by the hepatic enzyme CYP2E1 in the liver.The compound is selected from the following group: Tween 20, microcrystalline cellulose, dicalcium phosphate, polyoxyethylene 23 lauryl ether, saccharin, mannitol, polyoxyethylene alkyl ether, sucralose, pyrrolidone, sodium starch glycolate, S100 acrylic resin, sodium carboxymethylcellulose, polyoxyethylene polyoxyethylene, menthol, low-substituted propylcellulose hydrocarbon, pregelatinized starch, Dextrates NF hydrate, citric acid, polyoxyethylene castor oil, colloidal silicon, aliphatic polyethylene glycol monostearate ester, sorbic acid, lemon oil, hydroxypropylcellulose, sorbitol, acesulfame potassium, hypromellose phthalate, lactose monohydrate, maltodextrin, Brij 58, Brij 76, Tween 80, Tween 40, PEG 400, Peg 4000, PEG 2000, and the like, so as to reduce the side effects caused by acetaminophen on the liver.

This invention provides a quetiapine fumarate tablet composition and its preparation method. The composition contains the following components: quetiapine fumarate-hydroxypropyl-β-cyclodextrin co-treated product, povidone, calcium hydrogen phosphate, microcrystalline cellulose, sodium carboxymethyl starch, lactose monohydrate, magnesium stearate, and omeprazole. This invention also provides a method for processing a large-particle-size, highly fluid, highly soluble, and stable active pharmaceutical ingredient (API). This involves adding the API to a hydroxypropyl-β-cyclodextrin solution, homogenizing the resulting suspension, and spray-drying to prepare the quetiapine fumarate-hydroxypropyl-β-cyclodextrin co-treated product. The resulting intermediate powder obtained by wet granulation of the above-mentioned API-containing product exhibits superior flowability, smaller relative standard deviation of content uniformity, and a faster tableting rate after compression compared to tablets prepared solely from large-particle-size APIs, which is highly beneficial for industrial-scale production.

This invention relates to a fixed-dose dry powder inhalation formulation comprising fluticasone propionate and albuterol sulfate, together with an α-lactose monohydrate carrier. In the formulation, the albuterol sulfate stabilises fluticasone propionate.

The present disclosure provides oral dosage forms comprising about 8.75% w / w deuruxolitinib phosphate, about 50% to about 60% w / w microcrystalline cellulose, about 25% to about 35% w / w lactose monohydrate, about 3% to about 6% w / w polyvinylpyrrolidone, about 2% to about 4% w / w hydroxypropyl cellulose, about 0.25% to about 0.75% w / w colloidal silicon dioxide, and about 0.25% to about 0.75% w / w magnesium stearate.

The application belongs to the technical field of milk powder preparation, and particularly relates to a preparation process for improving lactose crystallinity in infant formula milk powder. The preparation process adds alpha-lactose monohydrate in the concentrated process before spray drying in the production of infant formula milk powder, and combines the optimization of the addition amount of alpha-lactose monohydrate, the concentration of concentrated milk and the temperature of concentrated milk to control the content of crystalline lactose in the concentrated milk solution, so as to accurately control the lactose crystallinity in the infant formula milk powder, and finally obtain high-quality infant formula milk powder with specific lactose crystallization characteristics, improve the storage stability of the product, break through the limitation that the traditional process cannot control the lactose crystallinity, fill the technical gap in the field, and provide a flexible and feasible technical scheme for improving the powder characteristics of infant formula milk powder.

Disclosed is a nintedanib esylate inhalation powder composed of micronized nintedanib esylate and lactose monohydrate. Further disclosed are a preparation method for the nintedanib esylate inhalation powder and use thereof in the preparation of a drug for treating pulmonary diseases such as pulmonary diseases with fibrosis or lung cancer.

The present application relates to the technical field of pharmaceutical preparation, and particularly discloses a felodipine enalapril tablet and a preparation method thereof. The felodipine enalapril tablet takes hydrochloric acid felodipine and maleic acid enalapril as active ingredients, and the auxiliary materials include lactose monohydrate, microcrystalline cellulose, crosslinked polyvinylpyrrolidone, sodium bicarbonate, povidone and magnesium stearate. The tablet is prepared through the processes of separate granulation, mixing, tabletting and coating. The felodipine enalapril tablet prepared by the present application has similar dissolution curve to the reference preparation, uniform content and good stability.

The invention discloses a composition and a preparation method of a masutentan tablet, the formula comprises masutentan, lactose (monohydrate), microcrystalline cellulose, povidone K30, croscarmellose sodium, magnesium stearate, polysorbate 80, L-cysteine and purified water, and the use amount of L-cysteine is 0.1%-0.9% of the use amount of the main drug masutentan. The masutentan tablet disclosed by the invention is simple in composition, stable in quality and simple and convenient in preparation process, and L-cysteine is adopted as an antioxidant, so that the oxidative degradation of the masutentan can be inhibited under a strong oxygen condition, the level of impurities generated after the masutentan is degraded is lower, the toxic and side effects of the medicine are further reduced, and the medication safety is improved.

Methods and apparatus for using Raman spectroscopy to identify and quantify lactose isomers in solid samples. In one example, a method is performed via a computing device for providing support to a Raman instrument and includes receiving from the Raman instrument a set of electrical readout signals representing a low-frequency Raman (LFR) spectrum of a solid sample including lactose. The method further includes the computing device estimating percentages of α-lactose monohydrate and anhydrous β-lactose in the total amount of lactose present in the solid sample using a selected multivariate chemometric model and further using the LFR spectrum.